Top View
- Drug Resistance of Human Immunodeficiency Virus and Overcoming It by Natural Products
- Ccr5 Antagonists in the Treatment of Treatment-Naïve Patients Infected with Ccr5 Tropic Hiv-1
- Atazanavir Inhibits SARS-Cov-2 Replication and Pro-Inflammatory Cytokine Production
- Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir Or Darunavir/Cobicistat
- Antiretroviral Therapy for the Treatment of HIV
- GLASS Methodology for Surveillance of National Antimicrobial Consumption
- Drug Interactions with Antiretroviral Medications
- ANTIRETROVIRAL CONTRAINDICATIONS and DRUG INTERACTIONS (Part of 5)
- Metabolic and Body Composition Effects of Newer Antiretrovirals in HIV-Infected Patients
- Urolithiasis in a Patient with HIV Receiving Atazanavir
- Switching to Rezolsta®/Prezcobix® (Darunavir+Cobicistat) Or Evotaz® (Atazanavir+Cobicistat)
- Recreational Drugs and HIV Antiretrovirals a Guide to Interactions for Clinicians
- Application for Listing of Atazanavir for the Treatment of Hiv-1 Infection on the Who Model List of Essential Medicines
- Parenteral Inhibitors of HIV Entry in Current Development The
- VIREAD® (Tenofovir
- Atazanavir Mylan, INN-Atazanavir Sulfate
- Potential Drug-Drug Interactions of Antiretrovirals and Antimicrobials
- Intraindividual Comparison of Efavirenz, Atazanavir, Or Ritonavir
- Efavirenz Versus Boosted Atazanavir Or Zidovudine and Abacavir in Antiretroviral Treatment–Naive, HIV-Infected Subjects: Week 48 Data from the Altair Study
- Selected Properties of Vicriviroc **In October 2005, Schering Plough
- Who Model List of Essential Medicines Application 1
- Efavirenz Versus Boosted Atazanavir Or Zidovudine and Abacavir In
- Descovy, INN-Emtricitabine / Tenofovir Alafenamide
- Once-Daily Atazanavir/Cobicistat and Darunavir/Cobicistat Exposure Over 72 H Post-Dose in Plasma, Urine and Saliva: Contribution to Drug Pharmacokinetic Knowledge
- November 2014 – Issue 38
- Ccr5 Antagonists in Hiv Therapy
- A Step-By-Step Approach in Caring for Our HIV-Infected Patients
- Reyataz, INN-Atazanavir
- 136 Superior Efficacy of Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Compared with Ritonavir Boosted Atazanavir Plus
- Abacavir Plasma Pharmacokinetics in the Absence and Presence of Atazanavir/Ritonavir Or Lopinavir/ Ritonavir and Vice Versa in HIV-Infected Patients
- Atazanavir (Reyataz)
- Guidelines for ATC Classification and DDD Assignment 2021
- REYATAZ (Atazanavir Sulfate) Capsules • Hepatotoxicity: REYATAZ Should Be Used with Caution in Patients with Initial U.S
- Vemlidy, INN-Tenofovir Alafenamide
- WO 2012/151165 Al 8 November 2012 (08.11.2012) P O P C T
- Guidelines for ATC Classification and DDD Assignment 2013
- Viramune (Nevirapine) Tablets
- ATAZANAVIR (Reyataz®) & RITONAVIR (Norvir®)
- Rezolsta, INN-Darunavir/Cobicistat
- Reference ID: 4173147
- GENVOYA Safely and Effectively
- Computational Studies of HIV-1 Protease Inhibitors
- Atazanavir PK Fact Sheet Reviewed March 2016 Page 1 of 2 for Personal Use Only
- REYATAZ (Atazanavir)
- REYATAZ Rx Only
- ARV-ARV Drug Combinations to Be Avoided (DUR POS Edits)
- Interactions Between Opioids and Antiretrovirals
- Safety and Effectiveness of Tenofovir/Emtricitabine Or
- Atazanavir/Cobicistat